BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12218955)

  • 1. Clinical and pharmacokinetic study of fractionated doses of oral etoposide in pediatric patients with advanced malignancies.
    Gregianin LJ; Brunetto AL; Di Leone L; Costa TD; Santos PP; Schwartsmann G
    Med Sci Monit; 2002 Sep; 8(9):PI70-7. PubMed ID: 12218955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
    Advani R; Fisher GA; Lum BL; Jambalos C; Cho CD; Cohen M; Gollerkeri A; Sikic BI
    Clin Cancer Res; 2003 Nov; 9(14):5187-94. PubMed ID: 14613998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
    Yong WP; Desai AA; Innocenti F; Ramirez J; Shepard D; Kobayashi K; House L; Fleming GF; Vogelzang NJ; Schilsky RL; Ratain MJ
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):811-9. PubMed ID: 17308893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
    Cunningham C; Appleman LJ; Kirvan-Visovatti M; Ryan DP; Regan E; Vukelja S; Bonate PL; Ruvuna F; Fram RJ; Jekunen A; Weitman S; Hammond LA; Eder JP
    Clin Cancer Res; 2005 Nov; 11(21):7825-33. PubMed ID: 16278405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors.
    Sonnichsen DS; Ribeiro RC; Luo X; Mathew P; Relling MV
    Clin Pharmacol Ther; 1995 Jul; 58(1):99-107. PubMed ID: 7628187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
    Gelderblom H; Salazar R; Verweij J; Pentheroudakis G; de Jonge MJ; Devlin M; van Hooije C; Seguy F; Obach R; Pruñonosa J; Principe P; Twelves C
    Clin Cancer Res; 2003 Sep; 9(11):4101-7. PubMed ID: 14519632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetic aspects of oral administration of etoposide].
    Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
    Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
    Sood AK; Lush R; Geisler JP; Shahin MS; Sanders L; Sullivan D; Buller RE; Sorosky JI
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6080-5. PubMed ID: 15447993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
    Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors.
    Bomgaars LR; Megason GC; Pullen J; Langevin AM; Dale Weitman S; Hershon L; Kuhn JG; Bernstein M; Blaney SM
    Pediatr Blood Cancer; 2006 Aug; 47(2):163-8. PubMed ID: 16317728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
    Zhu AX; Clark JW; Ryan DP; Meyerhardt JA; Enzinger PC; Earle CC; Fuchs CS; Regan E; Anbe H; Houghton M; Zhang J; Urrea P; Kulke MH
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):285-93. PubMed ID: 16786333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
    Rocha Lima CM; Catapano CV; Pacheco D; Sherman CA; Oakhill G; Mushtaq C; Freeman KD; Green MR
    Cancer; 2004 Jun; 100(12):2671-9. PubMed ID: 15197811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
    Lockhart AC; Bukowski R; Rothenberg ML; Wang KK; Cooper W; Grover J; Appleman L; Mayer PR; Shapiro M; Zhu AX
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):203-9. PubMed ID: 17091249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
    ; Fouladi M; Furman WL; Chin T; Freeman BB; Dudkin L; Stewart CF; Krailo MD; Speights R; Ingle AM; Houghton PJ; Wright J; Adamson PC; Blaney SM
    J Clin Oncol; 2006 Aug; 24(22):3678-85. PubMed ID: 16877737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of paclitaxel, cisplatin, and fluorouracil (TCF) for advanced gastric cancer.
    Hara T; Omura K; Hirano M; Asada Y; Munemoto Y; Sakamoto J
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):631-6. PubMed ID: 16924496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
    Soepenberg O; de Jonge MJ; Sparreboom A; de Bruin P; Eskens FA; de Heus G; Wanders J; Cheverton P; Ducharme MP; Verweij J
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):703-11. PubMed ID: 15701859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.